Lesson
Appropriateness, Timing, and Goals
Parenteral nutrition is reserved for a patient whose nutrition needs cannot be met safely or sufficiently through the gastrointestinal tract.
- Indications and alternatives
- Nutrition risk and timing
- Hemodynamic readiness
- Goals, ethics, and reassessment
Oral and enteral intake cannot meet the clinical target
→Digestion, absorption, or intestinal access is inadequate
→Nutrition risk and expected duration justify intravenous support
→Hemodynamics and metabolic abnormalities can be managed safely
Distinguish nutrition support routes
The book defines enteral nutrition as nutrient delivery through the gastrointestinal tract, including oral food or a formula delivered to the stomach or intestine. PN delivers calories into a vein. When the gut functions and can maintain nutritional status, EN is preferred because it is more physiologic, generally less expensive and has fewer complications. A need for nutrition support does not by itself select the intravenous route.
Use the source indication in its context
The source describes inability to absorb adequate gastrointestinal nutrition for more than five days as a possible PN indication. Its examples include bowel obstruction, ileus, severe diarrhea, radiation enteritis and untreatable malabsorption. The wording is a source indication discussion, not a mandatory waiting period for every patient or a complete timing algorithm for all degrees of malnutrition.
Recognize the added route burden
Compared with EN, PN is more invasive and less physiologic, with higher infection and thrombosis risk. The book also describes lower hyperglycemia, cholelithiasis and cholestasis risk with EN, along with preservation of the gut. These route distinctions belong alongside whether the patient can actually absorb enough nutrition; they do not make PN unnecessary when the gastrointestinal route cannot meet the need.
Require both need and route failure
Parenteral nutrition delivers amino acids, dextrose, lipid, electrolytes, vitamins, trace elements, and water directly into the circulation. It is appropriate when clinically important nutrition needs exist and oral or enteral delivery is impossible, contraindicated, or persistently insufficient. A central line that already exists is not an indication by itself.
Recognize common indications
Examples include intestinal obstruction or severe dysmotility, major malabsorption, short bowel syndrome, high-output fistula without usable distal access, prolonged ileus, and selected cases of severe pancreatitis or gastrointestinal bleeding when enteral delivery fails. The diagnosis alone does not settle the decision. Anatomy, absorption, severity, expected duration, and realistic alternatives still matter.
Time therapy to nutrition risk
ASPEN's adult appropriateness recommendations distinguish three settings. Start PN after seven days in a stable, well-nourished adult who has been unable to receive at least 50% of estimated needs orally or enterally. For a nutritionally at-risk adult unlikely to achieve adequate oral or enteral intake, start within three to five days. With baseline moderate or severe malnutrition and insufficient or impossible gastrointestinal delivery, start as soon as feasible. Severe metabolic instability warrants a delay until it improves. Assess gastrointestinal feasibility, actual intake and nutrition status together; the book's more-than-five-days indication statement is not a universal waiting rule.
Stabilize before aggressive delivery
Severe metabolic instability, uncontrolled shock and major fluid or electrolyte abnormalities can make immediate full-dose PN unsafe. Stabilize perfusion and fluid balance and assess refeeding risk before advancing energy. ASPEN advises delaying calorie initiation or increases when phosphate, potassium or magnesium is severely low until the deficits are corrected; milder deficits require supplementation and an individualized decision about holding calories. An indication for early PN does not mean immediate delivery of the full target. Discuss expected benefits, burdens, patient preferences and criteria for reassessment or stopping. If benefit is uncertain, a time-limited trial can be considered with goals and review criteria agreed before it starts.
Quick check
Checking for saved practice…
Lesson
Venous Access and Catheter Safety
The final admixture concentration, expected duration, vascular anatomy, infection risk, and care setting determine the access strategy.
- Peripheral versus central delivery
- PICC, tunneled catheter, and port
- Tip location and line integrity
- Infection and thrombosis prevention
Lower osmolarity, larger volume, frequent site review
→Central tip with thrombosis and vein-preservation considerations
→Durable external access for selected home therapy
→Intermittent access with needle and care requirements
Keep the peripheral option short and conditional
The source states that peripheral PN may be possible for short-term use, less than one week, but emphasizes phlebitis and vein damage. It does not make every short course suitable for peripheral delivery. Central access permits greater osmolarity and a wider pH range; the formulation and the required volume must still fit the patient.
Identify central access by where it ends
The intravenous-principles chapter explains that a central line empties into a large vessel where the contents are rapidly diluted. A PICC begins in a peripheral vein but its tip is advanced centrally, with the book figure showing the superior vena cava. The PN chapter also names Hickman, Broviac and Groshong lines. The insertion site alone does not classify the delivered infusion as peripheral.
Separate two compatibility questions
The book distinguishes additive compatibility in the same container from Y-site compatibility during brief mixing in shared tubing. A pair can have different results in these two settings because the contact conditions differ. Use the reference entry for the actual concentrations, diluent and administration method; a Y-site result does not establish compatibility for adding a drug to the PN bag.
Use peripheral PN as a limited bridge
ASPEN's adult appropriateness guidance limits peripheral PN to short-term supplemental or bridge therapy, no more than 10-14 days, with an upper osmolarity limit of 900 mOsm/L. This differs from the book's less-than-one-week example and does not override a stricter product or local requirement. The July 2025 SMOFlipid label requires central access for an admixture at 900 mOsm/L or above. Dilution can require more fluid than the patient tolerates or prevent adequate protein, energy or electrolyte delivery. Assess fluid allowance, kidney function and venous integrity, and watch for phlebitis, infiltration and extravasation injury. A short course alone does not establish peripheral suitability.
Use central access for concentrated therapy
Central venous access permits higher final concentrations because blood flow in a large vessel rapidly dilutes the admixture. Select a PICC, nontunneled catheter, tunneled catheter or implanted port according to expected duration, urgency, anatomy, thrombosis risk, care setting and the patient's or caregiver's ability to manage it. ASPEN's adult home-PN guideline suggests a tunneled device for anticipated long-term daily infusions; a PICC may be used when duration is uncertain or short. These suggestions rely on limited observational evidence and do not guarantee freedom from complications. In advanced chronic kidney disease, preserve peripheral and central veins for possible future dialysis access. The MAGIC panel rated arm PICCs and midlines inappropriate in stage 3b or greater CKD and discussed alternative central access. Involve nephrology when kidney-disease severity is uncertain and individualize the plan for urgency, likely dialysis needs and available alternatives.
Confirm and protect the system
The catheter tip and device function must be confirmed according to device, insertion method, and facility policy before use. Use the fewest lumens necessary, minimize connections and manipulations, and avoid routine medication coadministration. A dedicated PN lumen can help separate incompatible infusions and reduce unnecessary access; ASPEN prefers it when feasible. CDC considers evidence for its infection-prevention benefit unresolved, so it does not replace hand hygiene, aseptic hub access or the catheter-care bundle. A compatibility check does not remove infection risk.
Treat line findings as clinical signals
Fever or chills during infusion, redness, drainage, tenderness, resistance, arm or neck swelling, catheter migration or unexplained loss of function requires prompt assessment. Fever when a PN cycle begins can signal catheter colonization; obtain appropriate blood cultures and evaluate other causes rather than treating the timing as proof of infection. Stop an affected infusion and assess safely when an acute reaction or catheter problem is suspected. Fever alone does not require automatic catheter removal. Hand hygiene, aseptic hub access, appropriate skin antisepsis, dressing care and review of line necessity remain central to prevention. Routine systemic antibiotics or anticoagulants are not used solely to prevent catheter infection.
Quick check
Checking for saved practice…
Lesson
Macronutrient and Fluid Design
A safe prescription integrates protein, dextrose, lipid, non-PN energy, fluid, organ function, and the patient's metabolic capacity.
- Amino acids and nitrogen
- Dextrose and glucose infusion rate
- Lipid injectable emulsions
- Energy, fluid, and non-PN calories
Fit the nutrient plan inside the fluid prescription
→Match protein to illness, losses, organ support, and goals
→Check glucose infusion rate and glycemic tolerance
→Account for essential fatty acids and non-PN calories
Set the fluid allowance before distributing nutrients
The book determines fluid requirements first when designing PN. It then tailors that estimate to the patient, reduces fluid when accumulation is a concern and counts medication fluids, including intravenous piggybacks, in the overall delivered volume. Establish that allowance before fitting stock solutions and nutrients into the prescription. A calculated daily estimate does not by itself settle the final formulation or access route.
Name the protein basis and energy convention
The book gives protein examples of 0.8 to 1 g/kg/day for a non-stressed ambulatory patient and 1.2 to 2 g/kg/day for hospitalized or malnourished patients. It uses total body weight for most PN calculations unless another basis is specified, while some protein orders specify IBW. It also distinguishes a nonprotein calorie goal from a total-energy goal that includes amino acids. State the weight and calorie convention before solving the order.
Keep lipid energy and schedule together
The source uses 1.1 kcal/mL for 10% injectable lipid emulsion, 2 for 20% and 3 for 30%, rather than simply applying the food-fat value of 9 kcal/g. It distinguishes four-oil Smoflipid from traditional soybean-oil emulsion and warns against treating them as interchangeable. When triglycerides are high, the source discusses reducing lipid frequency to three times weekly or once weekly. A weekly calorie average does not change the prescribed schedule.
Count energy actually supplied outside PN
The book directs counting lipid calories from propofol and clevidipine alongside PN. Its rendered critical-care table gives propofol 1.1 kcal/mL. Use the stated or delivered medication volume and the same time period as the nutrition ledger. In an original arithmetic exercise, 14 mL/hour for eight hours supplies 112 mL, or 123.2 kcal at that stated density. The result is an energy contribution, not an anesthetic dose recommendation.
Set protein from clinical demand
Amino acids provide 4 kcal per gram but are prescribed primarily to support protein synthesis and limit net protein loss. Assess illness severity, wounds and other losses, body composition, renal replacement therapy, liver disease, and goals of care. Dialysis can increase amino acid losses. In critically ill patients, kidney or liver dysfunction alone does not justify automatic protein restriction; protein should not be restricted just to postpone dialysis. These principles do not establish one dose for every patient with chronic kidney disease. Reassess the amount actually delivered and the clinical response; albumin alone cannot determine protein adequacy.
Advance dextrose within metabolic capacity
Dextrose provides 3.4 kcal per gram. The glucose infusion rate expresses delivery relative to weight and infusion time; it supports prescribing but does not replace glucose monitoring. Count dextrose-containing intravenous fluids and medication vehicles in total exposure. Excess energy can worsen glycemic control and increase lipogenesis and carbon dioxide production, particularly in patients prone to carbon dioxide retention. Rising triglycerides or hepatic abnormalities also warrant review of total energy and tolerance. Assess fluid balance separately and investigate illness, medicines, and other causes rather than treating any one abnormality as proof of overfeeding.
Prescribe lipid as a drug product
Lipid injectable emulsions provide energy and essential fatty acids, but composition, concentration, maximum rate, allergy information, age indication, and compatibility are product specific. Count lipid from propofol and clevidipine. Monitor triglycerides and clinical tolerance. Current ASPEN adult guidance recommends limiting or holding ILE when triglycerides exceed 400 mg per dL, while avoiding prolonged lipid omission that can cause essential fatty acid deficiency.
Screen the actual lipid product for allergy
Allergy screening must use the actual lipid emulsion. SMOFlipid contains soybean oil, fish oil and egg phospholipids, and its July 2025 label contraindicates use in patients with known hypersensitivity to fish, egg, soybean, peanut or any ingredient. Peanut is a labeled allergy contraindication, not a listed active oil ingredient; the label describes soybean-peanut cross-reactivity. If a hypersensitivity reaction occurs, stop SMOFlipid immediately and provide appropriate treatment and support. A different oil blend does not make all lipid products interchangeable or remove product-specific allergy review.
Make volume and route agree
The total volume must include macronutrient stock solutions, electrolytes, vitamins, trace elements, medications added to the bag, and sterile water. A fluid-restricted patient may require central access and a more concentrated formulation. A patient with high gastrointestinal or renal losses may need additional replacement outside PN. Avoid treating a generic milliliter-per-kilogram estimate as a fixed prescription.
Quick check
Checking for saved practice…
Lesson
Electrolytes, Vitamins, and Trace Elements
Micronutrient dosing begins with standard adult needs, then changes with organ function, measured deficits, abnormal losses, duration, and product availability.
- Electrolyte pattern and acid base
- Parenteral multivitamins
- Trace elements and toxicity
- Shortages and individualized supplementation
Kidney function, acid base state, losses, and medicines
→Use an age-appropriate complete parenteral product when available
→Check product content, cholestasis, losses, and duration
→Use current product-specific guidance and reassess as supply recovers
Name the salt and count its second ion
Sodium can be supplied by chloride, acetate or phosphate salts; potassium can be supplied by chloride, acetate or phosphate salts. The book explains that sodium acetate is converted to bicarbonate and can help address the delivered acid-base pattern when acidosis is present. A phosphate order specifies mmol and the salt form. Sodium and potassium phosphate products do not supply equivalent amounts, so a stock contributes both phosphate and its sodium or potassium counterion.
Apply the source precipitation precautions with their limits
The source prefers calcium gluconate over calcium chloride because less free calcium is available to bind phosphate. It describes phosphate addition after dextrose and amino acids, agitation, and calcium addition near the end at the larger volume. Lower pH and refrigeration reduce the described precipitation risk; increasing temperature increases dissociation. The source solubility curve and combined 45 mEq/L screen are not interchangeable with proof that an actual product and process are compatible. A screen below a threshold alone does not establish compatibility.
Distinguish the vitamin mixtures and warfarin review
The book MVI-13 mixture includes four fat-soluble vitamins, A, D, E and K, plus nine water-soluble vitamins. Its MVI-12 mixture omits vitamin K. Thiamine is one of the listed water-soluble vitamins. If a PN patient receives warfarin, the source specifically calls for INR monitoring. Identify the actual mixture; the number in its name does not mean every product or patient has the same vitamin K plan.
Attribute the source trace-element groups
The source mix includes zinc, copper, chromium and manganese, with selenium possibly included. Its severe liver-disease discussion identifies manganese and copper for withholding; its severe renal-disease discussion names chromium, molybdenum and selenium. These are the 2023 book review groups, rather than an automatic instruction to omit an entire present-day multi-trace product. Select and review the actual components for the patient. The source also states that iron is not routinely given in PN.
Keep other medications from becoming routine ingredients
The book describes multivitamins and trace elements as usual additions, with insulin and H2 receptor antagonists occasionally added. Other IV medication additions are generally discouraged: stopping or changing that drug during the day can waste the entire PN preparation. Drug-in-bag compatibility remains a separate question from Y-site compatibility; the occasional examples are not permission to add any requested medication.
Prescribe electrolytes as a pattern
Individualize sodium, potassium, magnesium, calcium, phosphate, chloride, and acetate using laboratory trends, kidney function, urine and gastrointestinal output, medicines, acid-base status, and replacement from other sources. Count both ions supplied by each salt rather than adjusting one in isolation. Acetate can provide base equivalents after metabolism and changes the amount of chloride delivered. Avoid bicarbonate salts in the PN admixture because they can promote incompatibility and precipitation, including calcium and magnesium salts. Published dose ranges are starting references; a changing patient and validated formulation limits determine the final prescription.
Protect calcium and phosphate compatibility
Calcium-phosphate precipitation can be fatal and cannot be predicted safely from a single concentration rule. Risk changes with the calcium salt, phosphate salt, amino acid product and concentration, dextrose concentration, pH, temperature, order of mixing, final volume, and storage. Use validated product-specific compatibility data and compounding software, add phosphate early and calcium late when required by the validated process, and inspect the final preparation.
Provide complete vitamins
Include a full age- and patient-appropriate parenteral multivitamin dose daily from the beginning of PN unless contraindicated. Commercial multichamber PN also requires a vitamin plan, and patients receiving PN less than daily still need vitamin provision addressed on non-PN days. Follow the product and formulation instructions for mixing, storage, and light protection; vitamins can degrade with time, oxygen, and light. Additional preventive thiamine is required for adults at refeeding risk according to the refeeding protocol. During a shortage, use current product-specific ASPEN guidance, document substitutions and monitoring, and restore routine provision when supply recovers. Oral or enteral substitution requires a usable route, adequate absorption, and a complete vitamin profile; a pediatric product or an incomplete oral supplement is not automatically an equivalent adult replacement.
Give thiamine before refeeding
In an adult at risk for refeeding syndrome, ASPEN recommends 100 mg of thiamine before feeding or before starting dextrose-containing IV fluids. With severe starvation, chronic alcohol use or other high risk for thiamine deficiency, continue 100 mg daily for five to seven days or longer. This preventive recommendation does not replace treatment of a suspected deficiency syndrome. Include a daily PN multivitamin unless contraindicated; routine thiamine levels do not guide this preventive step.
Individualize trace elements
Check the actual elements and amounts in the selected product. For example, the FDA Tralement label lists zinc, copper, manganese, and selenium; it does not contain chromium. A fixed combination is unsuitable when the patient needs less of one component, so individual products may be needed. High gastrointestinal losses and severe burns can increase zinc requirements; this does not justify increasing every trace element together. Consider kidney function, organ support, wounds, losses, and duration during reassessment. Cholestasis can increase copper and manganese accumulation risk. New neurologic symptoms during manganese exposure require prompt assessment; for suspected Tralement-associated toxicity, temporarily discontinue the product and evaluate whole-blood manganese and other causes. Reassess reduced or withheld elements to avoid deficiency. Routine iron addition to a TNA is avoided because of formulation-specific compatibility and safety concerns; assess iron status and replacement separately.
Quick check
Checking for saved practice…
Lesson
Formulation, Compounding, and Administration Safety
Parenteral nutrition is a high-alert compounded sterile preparation whose physical, chemical, microbial, and labeling safety must be verified as one system.
- Two-in-one and total nutrient admixtures
- Emulsion stability
- USP sterile compounding
- Filtration, labeling, and final verification
Dose, units, route, sequence, allergies, and clinical fit
→Product-specific calcium, phosphate, pH, and emulsion compatibility
→Particles, precipitate, oiling, leakage, label, and final composition
→Current ASPEN recommendation for all PN formulations
Communicate the preparation on its label
The book sterile-preparation chapter requires labels to identify ingredient names and amounts or concentrations, total volume, beyond-use date, route and storage requirements, with other information needed for safe use. Auxiliary labels communicate special handling when required, such as a specified filter or light protection. These fields describe the preparation; a complete label does not itself establish the correct beyond-use date or prove ingredient compatibility.
Interpret color separately from particles
The book IV-principles table lists multivitamins for infusion as a yellow solution. Interpret color against the actual preparation rather than assuming that every parenteral ingredient must be colorless. The same page requires checking parenteral solutions for particulate matter and discarding a drug solution if particles are present. An expected ingredient color does not establish that the final PN admixture is compatible or particle-free.
Verify the measured ingredient before transfer
The book compounding chapter calls for the pharmacist to see the actual product volume in the syringe before compounding continues. Reconstructing the volume later by pulling back an empty syringe relies on memory and is not the recommended verification method. It also describes inspecting finished sterile preparations promptly for particles, cored fragments and precipitates, and checking for leakage. Ingredient quantity verification and finished-product inspection address different possible errors.
Recognize premixed chambers and their contents
Both two-in-one and three-in-one PN formulations contain water, electrolytes, vitamins and minerals; the macronutrient distinction is whether lipid is in the same container. The book describes two-chamber premixed products with amino acids in one chamber and dextrose in the other. The separating seal is broken to mix them before administration. Three-chamber products include a lipid chamber. Clinimix-E is the source example containing electrolytes.
Connect sterile preparation and physical compatibility
The book identifies PN as a compounded sterile product governed by USP chapter 797 and as a high-alert medication. Its intravenous-principles discussion separates physical incompatibility, such as precipitation, from chemical degradation. Stability depends on concentration, time, temperature and light exposure. Preparing a sterile bag and establishing ingredient compatibility are different requirements; success at one does not establish the other.
Choose a formulation deliberately
A two-in-one admixture contains dextrose and amino acids, with lipid infused separately when prescribed. A total nutrient admixture combines all three in one container. Combining lipid reduces the number of nutrient containers but adds emulsion-stability constraints; separate lipid delivery still requires compatibility review at any shared infusion site. Inspect the preparation, but a normal appearance cannot exclude subvisible particles or chemical instability. Select the formulation using validated compatibility and stability data and the patient's nutrient needs. Confirm the applicable tubing, filtration, storage, and administration-time requirements rather than assuming every formulation uses the same workflow.
Recognize emulsion failure
Lipid droplets are kept apart by the emulsifier and its electrostatic barrier. Excess cations, unfavorable pH, inappropriate concentrations, temperature, time and incompatible additives can promote aggregation, coalescence or irreversible cracking. Early aggregation or creaming may be reversible, but coalescence and free oil represent unsafe failure; do not try to rescue a cracked admixture by shaking it. Quarantine a preparation with visible oiling, precipitate, particles, unexpected color, leakage or container damage and obtain pharmacist review. Normal appearance alone cannot establish compatibility.
Apply current sterile-compounding standards
PN compounding must follow the current official USP chapter 797, applicable law, manufacturer instructions and facility quality systems. Category 1, 2 and 3 requirements have replaced the former low, medium and high risk labels. Assign the beyond-use date using the applicable category, preparation environment, process, sterility assurance, product-specific stability, container and storage conditions. Category 3 requires additional quality controls; a longer category limit does not override a shorter stability or manufacturer limit. Do not assign every PN bag the same refrigerated duration.
Filter every PN formulation
ASPEN recommends a 1.2 micron in-line filter for total nutrient admixtures, dextrose-amino acid admixtures and separate lipid emulsions. This replaces the older 0.22 micron convention for lipid-free PN. For a TNA, place the filter near the catheter hub. When separate lipid and dextrose-amino acid solutions co-infuse, place it downstream of their Y-site so both pass through it. Prime according to the manufacturer and change the filter with the new PN bag and administration set. Filtration reduces particulate exposure and is not a substitute for infection prevention. Avoid medication coadministration; unavoidable use requires pharmacist compatibility review, appropriate flushing and a Y-site upstream of the filter. Do not co-infuse a medication that must not be filtered.
Distinguish dating from administration time
The beyond-use date determines when administration may begin; it is not the same as the allowable infusion or hang time. USP chapter 797 does not itself establish administration duration. Begin before the assigned BUD, then follow the product, tubing and administration requirements for completing the infusion. A later category limit cannot justify longer storage than the actual formulation supports, and moving a bag to colder storage does not extend its original assigned BUD.
Investigate an occluded filter without bypassing it
For a high-pressure alarm, first check the pump pressure setting, clamps, tubing kinks, dressing and catheter patency under the local protocol. Confirm the correct 1.2 micron filter. If the filter is occluded, consider particulate matter and delayed precipitation, which can develop hours after compounding. Replace it with the same pore size and obtain a pharmaceutical review of the formulation and recurrent occlusion. Never continue PN through an unfiltered line to silence the alarm.
Quick check
Checking for saved practice…
Lesson
Monitoring, Complications, Cycling, and Transition
Monitoring connects what was prescribed and infused to nutrition response, metabolic tolerance, organ effects, catheter safety, and readiness to use the gut.
- Early and ongoing monitoring
- Refeeding and glycemic safety
- PN-associated complications
- Cycling, home PN, and transition
Watch phosphate, potassium, magnesium, fluid, and glycemia
→Weight, intake, output, liver, kidney, triglycerides, and line
→Change hourly exposure carefully and monitor starts and stops
→Reduce PN as oral or enteral delivery becomes reliable
Account for insulin adsorption to the container
The IV-principles chapter distinguishes absorption into a container from adsorption onto its surface. It specifically states that insulin adsorbs to PVC and that insulin infusion rates are adjusted to achieve blood glucose control regardless of the IV container or tubing used. This adds a delivery consideration to the PN insulin discussion. It does not provide a fixed replacement percentage or justify increasing a PN insulin dose without reassessment.
Watch the specific source monitoring concerns
The PN discussion requires assessment of glucose intolerance and refeeding syndrome, emphasizing intracellular electrolyte loss, particularly phosphate, and serious complications. It also tailors fluid to accumulation concerns such as heart failure or renal dysfunction, individualizes electrolytes and reviews high triglycerides. These source concerns accompany the calculation; a correct calorie sum does not show that the patient tolerates the regimen.
Read the insulin example without turning it into a fixed order
The source notes that PN may require insulin even without pre-existing diabetes. It illustrates regular insulin in the bag using half of the previous day's sliding-scale requirement or less, with supplemental subcutaneous insulin when needed, and describes PN being titrated on and off to support glucose regulation. This is the book's example, not an automatic insulin or taper order for every patient. In a stated arithmetic exercise only, half of a supplied 24-unit prior requirement is 12 units; the calculation alone does not determine an actual bag dose.
Assess depletion before calories return
Refeeding can follow oral, enteral or parenteral nutrition, including dextrose-containing IV fluids. Poor intake, weight loss, malabsorption and recent electrolyte depletion inform risk; normal serum potassium, magnesium or phosphate does not exclude depleted body stores. Rising insulin promotes potassium and phosphate movement into cells during renewed carbohydrate metabolism. Magnesium can also fall, but its refeeding mechanism is less clearly established. Monitor all three rather than treating phosphate as the only relevant electrolyte.
Start adult refeeding with a measured plan
For adults at risk, ASPEN's 2020 consensus suggests 100-150 g of dextrose or 10-20 kcal/kg during the first 24 hours, then an increase of about one-third of the goal every one to two days as clinical findings and electrolytes permit. Count dextrose from maintenance fluids and medication diluents, as well as nutrition. Prior tolerated dextrose exposure can affect the starting plan. These are general consensus recommendations, not a fixed order for every patient; special populations, including renal impairment, need individual assessment. Correct severely low potassium, magnesium or phosphate before starting or increasing calories.
Respond to refeeding changes promptly
Check potassium, magnesium and phosphate before feeding. In high-risk adults, ASPEN recommends checks every 12 hours for the first three days, with more frequent testing when indicated, and replacement according to established care standards. If levels fall rapidly or become difficult to correct, reduce calories or dextrose by 50% and reassess before advancing by about one-third of the goal every one to two days. Life-threatening deficits may require stopping nutrition support. Monitor vital signs every four hours for the first 24 hours, daily weights and intake/output; unstable patients or severe deficiencies warrant cardiorespiratory monitoring. Reassess nutrition goals daily until stabilized.
Monitor by phase and acuity
Before initiation, review allergies, nutrition status, clinical examination, medicines, glucose, electrolytes including calcium, magnesium and phosphate, kidney function, liver tests, blood counts and the planned nutrient and fluid delivery. During initiation or instability, monitor glucose, electrolyte shifts, hydration and clinical response closely; high-risk refeeding needs the more frequent checks described above. Continue weight, actual nutrient delivery, all fluid intake and losses, triglycerides, liver and kidney tests, catheter findings and infectious signs. ASPEN's general schedules rely largely on expert opinion and require individual adjustment. Stable home therapy can use longer intervals only after trends, follow-up and responsible clinicians are established; a new illness, formula change or abnormal result warrants reassessment.
Match lipid laboratory tests to the product
The July 2025 SMOFlipid label calls for monitoring triglycerides, fluid and electrolyte status, blood glucose, liver and kidney function, coagulation parameters and a complete blood count including platelets. Infused lipid can interfere with tests such as hemoglobin, lactate dehydrogenase, bilirubin and oxygen saturation; the label instructs sampling for these tests at least six hours after stopping the infusion. Coordinate sampling and interpretation with the clinical team. This product-specific instruction is not a reason to delay urgent evaluation or a universal sampling rule for every PN formulation.
Separate overfeeding from intolerance
Hyperglycemia, rising triglycerides, respiratory acidosis from excess carbon dioxide production, and hepatic abnormalities warrant review of energy delivery and metabolic tolerance. They are not specific for overfeeding: illness, medicines, lipid delivery, and impaired metabolism may contribute. Review all nutrition and medication calories, actual infusion rates, and fluid balance while treating clinically significant abnormalities promptly. Reducing an excessive prescription may be appropriate; adding insulin alone should not substitute for that review. Regular insulin may be included only when clinically appropriate and supported by compatibility and stability data. Reassess glucose and insulin exposure when delivery or clinical needs change, especially around infusion interruptions when separately administered insulin may continue to act.
Prevent and detect long-term complications
Long-term PN surveillance includes hepatobiliary disease, metabolic bone disease, micronutrient deficiency or excess and catheter complications. Liver and biliary abnormalities are multifactorial: consider illness, infection, overfeeding, lipid exposure and limited enteral stimulation rather than attributing every abnormal liver test to the PN bag. Monitor liver tests and evaluate biliary symptoms promptly. Provide balanced nutrients, avoid excess energy, preserve oral or enteral stimulation when appropriate and prevent infection. The SMOFlipid label also requires liver monitoring and consideration of dose reduction or discontinuation for abnormal tests; changing lipid brands does not guarantee prevention. Include bone-health assessment and targeted vitamin and trace-element review in the long-term plan rather than using one fixed laboratory panel indefinitely.
Cycle and transition with intent
Cyclic PN provides a daily infusion-free period and can support home routines, but delivering the daily amount over fewer hours increases hourly glucose, fluid and nutrient exposure. Assess tolerance during conversion and monitor glucose at the start and end of cycles; insulin given near the end can cause hypoglycemia after PN stops. Starting and stopping are individualized, and every stable adult does not require a taper. As gastrointestinal delivery becomes reliable, reduce PN according to measured intake, absorption and tolerance. Continue to assess weight, hydration, electrolytes and possible replacement fluids or oral vitamin and mineral needs, including follow-up after PN stops. A calendar date or one normal albumin result is insufficient.
Confirm readiness for home care
Before home PN discharge, confirm clinical stability, suitable access and a patient or caregiver who is willing and able to manage therapy. Assess the home environment and demonstrate understanding of catheter care, pump and administration procedures, storage, complication recognition, and tracking fluid intake and losses. Arrange the infusion provider, supplies, laboratory monitoring, follow-up visits and accessible accountable clinicians. Give clear instructions for fever or line problems and an emergency or readmission plan. A patent catheter and normal baseline tests do not replace demonstrated skills and support.
Reconcile each receiving prescription
At every care transition, communicate a complete PN order with the actual products, electrolyte salts, doses and units, plus the access and catheter-care plan. Include separate lipid infusions, supplemental fluids, associated medicines and vitamins, shipping or storage instructions, monitoring and follow-up responsibilities. Confirm that the receiving team has the products and skills required. If its formulary or stock differs, review the actual formulation and compatibility, adjust the order as needed and clearly communicate changes. Determine individually whether PN can be cycled off during transit or must continue; neither uninterrupted infusion nor automatic stopping is appropriate for every transfer.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 142 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ASPEN daily PN multivitamin practice tool (2023)
- ASPEN intravenous multivitamin shortage recommendations (2024)
- FDA Tralement prescribing information (2024)
- ASPEN parenteral micronutrient position paper (2012; published corrections)
- ASPEN/SCCM critical-care nutrition guideline: organ-specific considerations (2016)
- ASPEN critical-care nutrition guideline: energy and protein reassessment (2022)
- ASPEN adult home-PN central venous access guideline (2019)
- MAGIC catheter appropriateness: kidney disease and vein preservation (2015)
- ASPEN PN appropriateness consensus (2017)
- ASPEN ethical aspects of nutrition and hydration (2021)
- ASPEN safe PN care transitions practice tool (2022)
- ASPEN adult PN appropriateness and timing practice tool (2022)
- RxPrep 2023: PN formulation and monitoring
Chapter 11, printed 149-161 / PDF 157-169.
- RxPrep 2023: IV access and compatibility methods
Chapter 7, printed 100-105 / PDF 108-113.
- RxPrep 2023: Propofol calorie contribution
Chapter 53, printed 716 / PDF 724.
- RxPrep 2023: In-process sterile ingredient verification
Chapter 17, printed 277-278 / PDF 285-286. Quantity, inspection and label fields only; old risk categories and BUDs are not adopted.
- ASPEN parenteral nutrition clinical resources and care pathway
- ASPEN guidance on parenteral nutrition indications and appropriateness
- ASPEN update on in-line filters for parenteral nutrition
- ASPEN adult lipid injectable emulsion safety recommendations
- FDA SMOFlipid prescribing information (July 2025)
- USP chapter 797 sterile compounding standards
- ASPEN consensus recommendations for refeeding syndrome
- USP official FAQs: revised categories and beyond-use dating
- ASPEN compatibility and stability: comprehensive review
- ASPEN PN order review and verification checklist
- ASPEN PN compounding checklist
- ASPEN PN safety consensus: catheter and administration practices
- CDC catheter-care summary recommendations